

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



北京市春立正達醫療器械股份有限公司

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

ANNOUNCEMENT ON POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING

Reference is made to the circular of Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the “**Company**”) dated 20 September 2024 (the “**Circular**”), the notice of the Extraordinary General Meeting dated 20 September 2024 (the “**Notice**”). Unless otherwise indicated, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular and the Notice.

CONVENING AND ATTENDANCE OF THE MEETING

The Extraordinary General Meeting (the “**Meeting**”) of the Company was held at 2:00 p.m., on Tuesday, 15 October 2024 at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tongzhou District, Beijing, the PRC.

The Meeting was convened by the board of directors of the Company (the “**Board**”) and chaired by Ms. Shi Wenling, chairman of the Board. Voting at the Meeting was conducted by a registered poll onsite. Wuyige Certified Public Accountants LLP, the Company’s auditor, was appointed by the Company as the scrutineer for the voting.

The convening of the Meeting was in compliance with the requirements of the applicable laws and regulations of the PRC, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the articles of association of the Company.

The total number of issued Shares of the Company as at the date of the Meeting was 383,568,500 Shares, of which A Shares (the “**A Shares**”) and H Shares (the “**H Shares**”) were 288,428,000 shares and 95,140,500 shares, respectively, which was the total number of eligible shares that entitled the Shareholders to attend and vote for or against or abstain from voting on the resolution proposed at the Meeting.

No party has stated its intention in the Circular that it would vote against any resolution or that it would abstain from voting at the Meeting.

To the best knowledge, information and belief of the directors of the Company, there was no restriction on any shareholder casting votes on any of the proposed resolution at the Meeting. There were no Shares entitling the Shareholders to attend the Meeting and abstain from voting in favor as set out in Rule 13.40 of the Listing Rules and no Shareholders were required under the Listing Rules to abstain from voting at the Meeting.

All Directors attended the Meeting. The attendance record of the Directors at the Meeting was as follows:

- the executive Directors of the Company, Ms. Shi Wenling, Ms. Yue Shujun and Mr. Xie Feng Bao attended the Meeting in person; and
- the executive Director of the Company, Mr. Shi Chunbao, the non-executive Director of the Company, Mr. Wang Xin, and the independent non-executive Directors of the Company, Ms. Xu Hong, Mr. Wong Tak Shing and Mr. Weng Jie attended the Meeting by telephone.

Details about the attendance of the Shareholders and their authorized proxies at the Meeting are set out as follows:

Number of shareholders and authorized proxies attending the Meeting	70
Of which:	
Number of holders of A Shares	69
Number of holders of H Shares	1
Total number of the voting shares held by the attendees	223,478,483
Of which:	
Total number of shares held by holders of A Shares	212,053,319
Total number of shares held by holders of H Shares	11,425,164
Percentage of the total number of voting shares of the Company	58.32%
Of which:	
Percentage of the shares held by holders of A Shares to the total number of voting shares of the Company	55.34%
Percentage of the shares held by holders of H Shares to the total number of voting shares of the Company	2.98%

POLL RESULTS OF THE MEETING

The voting results in respect of the proposals at the Meeting are set out as follows:

Ordinary resolution		Number of votes & percentage of the total voting shares at the Meeting (%)		
		For	Against	Abstained
1.	To consider and approve the interim profit distribution plan for 2024.	223,363,148 (99.9484%)	101,631 (0.0455%)	13,704 (0.0061%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
2.	To consider and approve the Resolution on the Update of Expected Timeline and Change of Certain Proceeds-funded Projects.	223,070,387 (99.8174%)	371,119 (0.1661%)	36,977 (0.0165%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			

For the full text of the proposals, please refer to the Circular of the Company dated 20 September 2024.

PAYMENT OF INTERIM DIVIDEND

The Board announces that the proposal of payment of interim dividend of RMB0.83 per 10 Shares in cash (tax inclusive) for the six months ended 30 June 2024 (“**Interim Dividend**”) to all Shareholders was approved at the Meeting.

In order to determine the entitlement to the Interim Dividend, the Company’s register of members of H Shares will be closed from Monday, 21 October 2024 to Wednesday, 23 October 2024 (both days inclusive) during which period no transfer of H Shares will be effected. In order to be qualified for the Interim Dividend, all the transfer documents of the Company’s H Shares together with the relevant share certificates shall be lodged at the H Share registrar of the Company in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by no later than 4:30 p.m. on Friday, 18 October 2024 for registration. The Interim Dividend will be distributed to those Shareholders whose names appear on the register of members of the Company on Monday, 21 October 2024 in respect of H Shares.

The Interim Dividend will be paid to holders of A Shares in RMB and to holders of H Shares in HK dollar. The actual amount of H Share dividend paid in HK dollar will be calculated according to the average exchange rate of the relevant foreign exchange published by the People's Bank of China the mid-rate of seven business days prior to the date of approval of Interim Dividend in the Meeting. The average exchange rate of the relevant foreign exchange published by the People's Bank of China for the mid-rate of seven business days prior to the date of approval of Interim Dividend in the Meeting (i.e. 30 September 2024 to 14 October 2024) is 1:0.90735 (HK\$/RMB). Applying that average, the Interim Dividend for each H Share is HK\$0.091475. The Interim Dividend for the H Shares is expected to be paid on Friday, 13 December 2024.

The Company will withhold and pay the income tax strictly in accordance with the relevant laws or requirements of the relevant government authorities. For more information about the withholding tax, please refer to the Circular.

LEGAL ADVISERS AS TO PRC LAWS

The Extraordinary General Meeting was witnessed by lawyers from V&T Law Firm, Beijing, the PRC legal adviser of the Company, who concluded that the convening and convening procedures of the Extraordinary General Meeting are in compliance with the relevant requirements of the laws, administrative regulations and the articles of association of the Company. The eligibilities of the attendees, the convener of the Extraordinary General Meeting and the procedures and results of voting at the Extraordinary General Meeting were legal and valid.

By order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Shi Wenling
Chairman

Beijing, the PRC, 15 October 2024

As at the date of this announcement, the executive Directors of the Company are Ms. Shi Wenling, Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive Director of the Company is Mr. Wang Xin; and the independent non-executive Directors of the Company are Ms. Xu Hong, Mr. Wong Tak Shing and Mr. Weng Jie.

* For identification purposes only